JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 6, 2007; DOI: 10.1124/jpet.107.128926


0022-3565/08/3242-434-442$20.00
JPET 324:434-442, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.107.128926v1
324/2/434    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ong, V.
Right arrow Articles by Lock, R. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ong, V.
Right arrow Articles by Lock, R. B.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

A Role for Altered Microtubule Polymer Levels in Vincristine Resistance of Childhood Acute Lymphoblastic Leukemia XenograftsFormula

Vivienna Ong, Natalia L. M. Liem, Michael A. Schmid, Nicole M. Verrills, Rachael A. Papa, Glenn M. Marshall, Karen L. MacKenzie, Maria Kavallaris, and Richard B. Lock

Children's Cancer Institute Australia for Medical Research, Sydney, New South Wales, Australia (V.O., N.L.M.L., M.A.S., N.M.V., R.A.P., G.M.M., K.L.M., M.K., R.B.L.); University of New South Wales, Sydney, New South Wales, Australia (V.O., N.L.M.L., M.A.S., N.M.V., G.M.M., K.L.M., M.K., R.B.L.); and Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, Sydney, New South Wales, Australia (G.M.M.)

The microtubule-depolymerizing drug, vincristine, is effective in the treatment of acute lymphoblastic leukemia (ALL). Although vincristine resistance mechanisms have been extensively characterized in cell lines, their clinical relevance is poorly understood. The aim of the current study was to define clinically relevant mechanisms of vincristine resistance in a panel of childhood ALL xenografts established in immune-deficient (nonobese diabetic/severe combined immunodeficient) mice. We also studied two independent xenograft sublines that were selected by in vivo vincristine exposure. In vitro vincristine sensitivity determined by a stromal coculture, murine bone marrow stromal cell line (MS-5), assay, but not methyl-thiazolyl-tetrazolium metabolic activity assay, significantly correlated (P = 0.05) with the length of the patients' first remission. Investigations into mechanisms of resistance revealed no association with steady-state vincristine accumulation or increased activity and/or expression of ATP-binding cassette transporters, although increased intracellular levels of polymerized tubulin significantly correlated with resistance (r = 0.85; P = 0.0019). Two xenograft sublines selected by in vivo vincristine exposure exhibited a 2-fold increase in polymerized tubulin levels compared with the parental subline (P < 0.05), reflecting their in vivo vincristine resistance. In this study, a vincristine-resistant xenograft with high levels of polymerized tubulin was relatively sensitive to the microtubule-polymerizing drug paclitaxel. These results indicate that the balance between polymerized and nonpolymerized tubulin may be an important determinant of response to Vinca alkaloid-based chemotherapy regimens in childhood ALL.


Received July 19, 2007; accepted November 5, 2007.

Address correspondence to: Dr. Richard B. Lock, Children's Cancer Institute Australia, PO Box 81, High St., Randwick 2031, NSW, Australia. E-mail: rlock{at}ccia.unsw.edu.au







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.